NCT05798624 Impact of a Previous CS on the Ongoing Pregnancy Rate in Single Euploid Frozen Embryo Transfer (ET)
| NCT ID | NCT05798624 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ART Fertility Clinics LLC |
| Condition | Infertility |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,050 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2025-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,050 participants in total. It began in 2023-05-01 with a primary completion date of 2025-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As embryo ploidy is a crucial factor not only for implantation but also for maintenance of a pregnancy, the aim of this study is to evaluate the impact of the CS / isthmocele on the ongoing pregnancy rates and the implantation site in single euploid frozen embryo transfer, independent of the endometrial preparation approach.
Eligibility Criteria
Inclusion Criteria: \- All participants undergoing a single euploid FET, independent of the endometrial preparation approach Exclusion Criteria: * Intracavitary fluid during preparation for FET * Known anomaly of the uterus or the adnexae (e.g.: fibroids, polyps, hydrosalpinx, endometriosis, adenomyosis) * Embryo which was biopsied on day 7 * Poor quality embryo which was transferred (Gardner criteria: AC / BC / CB, biopsied on day 6 and CC embryos from both, day 5 and day 6 biopsies, classified as "poor" quality embryos) * History of recurrent abortion * Antiphospholipid syndrome / autoimmune diseases
Contact & Investigator
Barbara Lawrenz, PhD
PRINCIPAL INVESTIGATOR
ART Fertility Clinics LLC
Frequently Asked Questions
Who can join the NCT05798624 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 42 Years, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05798624 currently recruiting?
Yes, NCT05798624 is actively recruiting participants. Contact the research team at barbara.lawrenz@artfertilityclinics.com for enrollment information.
Where is the NCT05798624 trial being conducted?
This trial is being conducted at Abu Dhabi, United Arab Emirates.
Who is sponsoring the NCT05798624 clinical trial?
NCT05798624 is sponsored by ART Fertility Clinics LLC. The principal investigator is Barbara Lawrenz, PhD at ART Fertility Clinics LLC. The trial plans to enroll 1,050 participants.